This is an open-label, continuation study for participants receiving study intervention(s) in an encorafenib/binimetinib Parent Study. The study is being conducted under a Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies, with individual encorafenib/binimetinib continuation sub-study protocols that cover each eligible Parent Study. Up to approximately 210 participants from qualifying Parent Studies will be included in this Encorafenib/Binimetinib Continuation study.
This continuation study includes multiple sub-study protocols to allow participants from each of the following Parent Studies: C4211001 - NCT01320085; C4211003 - NCT01849874; C4221003 - NCT03864042; C4221004 - NCT01909453; C4221005 - NCT01543698; C4221006 - NCT03911869; C4221008 - NCT03915951; C4221009 - NCT02928224; C4221010 - NCT01436656; C4221013 - NCT02159066; ANCHOR-CRC - NCT03693170; C4221015 - NCT04607421; C4221016 - NCT04657991; C4221022 - NCT05217446; C4221023 - NCT05926960
